IRB approves additional enrollment in Cellceutix’s trial of nNew cancer drug candidate
Cellceutix announced the IRB overseeing the Company’s Phase 1 clinical trial of Kevetrin for treatment of advanced solid tumors being conducted at Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center has approved the amended protocol to allow additional patient enrollment. May 22, 2015